

Express Mail Label No. EV682328975US

Dated: March 6, 2006

Docket No.: IMI-044DV3CNRCE2  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Malcolm L. Geftter *et al.*

Application No.: 09/662784

Confirmation No.: 3152

Filed: September 15, 2000

Art Unit: 1649

For: A HUMAN T CELL REACTIVE FELINE  
PROTEIN (TRFP) ISOLATED FROM  
HOUSE DUST AND USES THEREFOR

Examiner: S. L. Turner

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)**

MS RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

For the Examiner's convenience in reviewing this continuing application, Applicants submit a consolidated PTO Form SB/08 listing all references cited during the prosecution of the parent application. These references were previously cited during the prosecution of U.S. Application Serial No. 08/431,184 (U.S. Patent No. 6,120,769), filed April 28, 1995 (Atty. Docket No. IMI-044DV3), of which this application is a continuation and to which this application claims priority. In accordance with 37 CFR 1.98(d), these references are not enclosed herewith, but will be provided upon request.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information

as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. IMI-044DV3CNRCE2. A duplicate copy of this paper is enclosed.

Dated: March 6, 2006

JMD/AEM/JER/SMW/mch

Respectfully submitted,

By   
Jeanne M. DiGiorgio  
Registration No.: 41,710  
LAHIVE & COCKFIELD, LLP  
28 State Street  
Boston, Massachusetts 02109  
(617) 227-7400  
(617) 742-4214 (Fax)  
Attorney/Agent For Applicant



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/662784-Conf. #3152
				Filing Date	September 15, 2000
				First Named Inventor	Malcolm L. GEFTER
				Art Unit	1649
				Examiner Name	S. L. Turner
Sheet	1	of	2	Attorney Docket Number	IMI-044DV3CNRCE2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1	4,163,778	08-07-1979	Ohman <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B1	WO-91/06571-A1	05-16-1991	Immologic Pharmaceutical Corporation		
	B2	WO-93/08280-A1	04-29-1993	Immologic Pharmaceutical Corporation		
	B3	WO-93/19178-A2	09-30-1993	Immunologic Pharmaceutical Corporation		
	B4	WO-92/15613-A1	09-17-1992	Immunologic Pharmaceutical Corporation		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Anderson, M.C. <i>et al.</i> , "A comparative study of the allergens of cat urine, serum, saliva, and pelt," <i>J. Allergy Clin Immunol.</i> , Vol. 76:563-569 (1985)	
	C2	Burgess, W. H. <i>et al.</i> , "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," <i>The Journal of Cell Biology</i> , Vol. 111:2129-2138 (1990)	
	C3	Chapman, M. D. <i>et al.</i> , "Monoclonal Antibodies to the Major Feline Allergen <i>fel d 1</i> , II. Single Step Affinity Purification of <i>Fel d 1</i> , N-Terminal Sequence Analysis, and Development of a Sensitive Two-Site Immunoassay to Assess <i>Fel d 1</i> Exposure," <i>The Journal of Immunology</i> , Vol. 140(3):812-818 (1988)	
	C4	de Groot, H. <i>et al.</i> , "Monoclonal antibodies to the major feline allergen <i>Fel d 1</i> ," <i>J Allergy Clin Immunol.</i> , Vol. 82:778-786 (1988)	
	C5	Didierlaurent, A. <i>et al.</i> , "Comparative Study on Cat Allergens from Fur and Saliva," <i>Int. Archs Allergy appl. Immun.</i> , Vol. 73:27-31 (1984)	
	C6	Duffort, O. <i>et al.</i> , "Monoclonal antibodies against <i>Fel d 1</i> and other clinically relevant cat allergens," <i>Immunology Letters</i> , Vol. 17:71-77 (1988)	
	C7	Duffort, O. <i>et al.</i> , "Characterization of the Main IgE-Binding Components of Cat Dander," <i>Int. Archs Allergy appl. Immun.</i> , Vol. 84:339-344 (1987)	
	C8	Jenkins, M.K. <i>et al.</i> , "Antigen Presentation by Chemically Modified Splenocytes Induces Antigen-Specific T Cell Unresponsiveness In Vitro and In Vivo," <i>Journal of Experimental Medicine</i> , Vol. 165:302-319 (1987)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/662784-Conf. #3152
				Filing Date	September 15, 2000
				First Named Inventor	Malcolm L. GEFTER
				Art Unit	1649
				Examiner Name	S. L. Turner
Sheet	2	of	2	Attorney Docket Number	IMI-044DV3CNRCE2

C9	Kumar, V. <i>et al.</i> , "Amino acid variations at a single residue in an autoimmune peptide profoundly affect its properties: T-cell activation, major histocompatibility complex binding, and ability to block experimental allergic encephalomyelitis," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 87:1337-1341 (1990)	
C10	Lazar, E. <i>et al.</i> , "Transforming Growth Factor $\alpha$ : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," <i>Molecular and Cellular Biology</i> , Vol. 8(3):1247-1252 (1988)	
C11	Leitermann, K. <i>et al.</i> , "Cat allergen 1: Biochemical, antigenic, and allergenic properties," <i>J Allergy Clin Immunol</i> , Vol. 74:147-153 (1984)	
C12	Lerner, R.A., "Tapping the immunological repertoire to produce antibodies of predetermined specificity," <i>Nature</i> , Vol. 299:592-596 (1982)	
C13	Löwenstein, H. <i>et al.</i> , "Identification and Clinical Significance of Allergenic Molecules of Cat Origin," <i>Allergy</i> , Vol. 40:430-441 (1985)	
C14	Margalit, H. <i>et al.</i> , "Prediction of Immunodominant Helper T Cell Antigenic Sites from the Primary Sequence," <i>The Journal of Immunology</i> , Vol. 138(7):2213-2229 (1987)	
C15	Mester, J.C. <i>et al.</i> , "The Mouse Model and Understanding Immunity to Herpes Simplex Virus," <i>Reviews of Infectious Diseases</i> , Vol. 13(Suppl. 11):S935-945 (1991)	
C16	Ohman, J. L. <i>et al.</i> , "Allergens of Mammalian Origin, III. Properties of a Major Feline Allergen," <i>The Journal of Immunology</i> , Vol. 113(6):1668-1677 (1974)	
C17	Ohman, J.L. <i>et al.</i> , "Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses," <i>J Allergy Clin Immunol</i> , Vol. 74:230-239 (1984)	
C18	Pongor, S. "The Use of Structural Profiles and Parametric Sequence Comparison in the Rational Design of Polypeptides," <i>Methods in Enzymology</i> , Vol. 154:450-473 (1987)	
C19	Salgaller, M.L. <i>et al.</i> , "Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide," <i>Cancer Immunology Immunotherapy</i> , Vol. 39:105-116 (1994)	
C20	Stone, K. L. <i>et al.</i> , "Enzymatic Digestion of Proteins and HPLC Peptide Isolation," <i>A Practical Guide to Protein and Peptide Purification for Microsequencing, Second Edition</i> , pp. 43-69 (1993)	
C21	Sundin, B. <i>et al.</i> , "Immunotherapy with partially purified and standardized animal dander extracts," <i>J Allergy Clin Immunol</i> , Vol. 77:478-487 (1986)	
C22	Ununue, "Immediate Hypersensitivity Reactions and Anaphylaxis," <i>Chapter 14, Textbook of Immunology, 2nd Edition</i> , pp. 281-298 (1984)	
C23	van Milligen, F.J. <i>et al.</i> , "IgE Epitopes of the Cat Allergen <i>Fel d</i> I; A Study with Overlapping Synthetic Peptides," <i>CLB and Lab Exp. Clin. Immunol., Univ. of Amsterdam, Abstracts</i> , Vol. 89(1, part 2):243 (1982)	
C24	Young, R.A. <i>et al.</i> , "Efficient isolation of genes by using antibody probes," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 80:1194-1198 (1983)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--